Why is the comparison with Medicare for CRESEMBA 186 MG CAPSULE labelled estimated?

Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Cresemba* / Isavuconazonium Sulfate: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's EA. Joined on brand name. *: CMS says this average reflects multiple routes of administration, which may have different unit prices. All 2 NADAC NDCs the name join matched to it have an FDA route including ORAL. 1 of the 2 NDCs that point at this name is not listed in the FDA NDC Directory as a package of its own; its route was taken from FDA's record for the same product (labeler and product code).

CRESEMBA 186 MG CAPSULE

FDA nonproprietary name: isavuconazonium sulfate

For 30 capsules

Pharmacies pay

$3,419.94 filed

30 × $113.99816 per EA

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D paid

$3,228.52 filed

30 × $107.61747 per EA, Part D average

Medicare's price is not your price.

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

The spread

0.94× estimated

Medicare paid 6% less than pharmacies pay.

Part D averages every strength and form sold under “Cresemba*” / “Isavuconazonium Sulfate” into one figure, so it is not specific to this NDC.

OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)

Cost-plus estimate

$3,937.93 estimated

$3,419.94 + $512.99 (15%) + $5.00 fee per fill = $3,937.93

This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out

OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)

Open the interactive card Change the quantity, type what you were charged, and see every record in full.

What it is

CRESEMBA 186 MG CAPSULE is how the CMS NADAC file names this product. The FDA NDC Directory lists it as isavuconazonium sulfate, under the trade name “CRESEMBA”.

FDA gives its dosage form as capsule and its route as oral.

The labeler, the company named on the label, is Astellas Pharma US, Inc.

FDA’s Established Pharmacologic Class for it is Azole Antifungal.

The NADAC file of 2026-10-14 prices it under 2 NDCs (National Drug Codes); the FDA directory lists 1 of them.

NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $3,419.94 for 30 capsules (30 × $113.99816 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation code for it: 1, calculated from the most recently completed pharmacy survey.

What NADAC measures · Why 30 capsules · NADAC explanation codes

All 2 NDCs

00469-0520-01 · not listed as a package in the FDA directory · $113.99816 per EA · eff. 2026-09-23 filed
00469-0520-02 · Astellas Pharma US, Inc. · $113.99816 per EA · eff. 2026-09-23 filed

Compared with its class

The middle of its 2 NDCs’ NADAC prices is $113.99816 per EA filed.

Of the 14 other products in FDA’s Azole Antifungal class priced per EA, 0 have a higher middle NADAC price and 14 a lower one. The one in the middle is KETOCONAZOLE 200 MG TABLET, at $0.64566 per EA filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

How the class comparison works

What Medicare paid

Medicare Part D paid $3,228.52 for 30 capsules, at an average of $107.61747 per EA in 2024 (2024-01-01 to 2024-12-31) for “Cresemba*” and “Isavuconazonium Sulfate”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 19,216 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

What is your cash price for 30 capsules? Is it lower than what I would pay through my insurance?
If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.

Questions

Why is the comparison with Medicare for CRESEMBA 186 MG CAPSULE labelled estimated?: Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Cresemba* / Isavuconazonium Sulfate: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's EA. Joined on brand name. *: CMS says this average reflects multiple routes of administration, which may have different unit prices. All 2 NADAC NDCs the name join matched to it have an FDA route including ORAL. 1 of the 2 NDCs that point at this name is not listed in the FDA NDC Directory as a package of its own; its route was taken from FDA's record for the same product (labeler and product code).

Its pharmacologic class

Azole Antifungal 61 products